| Market Cap | 718.28M | P/E | - | EPS this Y | 56.80% | Ern Qtrly Grth | - |
| Income | -24.41M | Forward P/E | 24.00 | EPS next Y | 284.40% | 50D Avg Chg | 7.00% |
| Sales | 130.19M | PEG | -2.08 | EPS past 5Y | - | 200D Avg Chg | 21.00% |
| Dividend | N/A | Price/Book | 29.01 | EPS next 5Y | 15.00% | 52W High Chg | -25.00% |
| Recommedations | 1.70 | Quick Ratio | 2.45 | Shares Outstanding | 35.36M | 52W Low Chg | 223.00% |
| Insider Own | 14.59% | ROA | 0.22% | Shares Float | 26.50M | Beta | 0.50 |
| Inst Own | 66.49% | ROE | -50.00% | Shares Shorted/Prior | 5.92M/5.50M | Price | 21.12 |
| Gross Margin | 69.55% | Profit Margin | -18.75% | Avg. Volume | 599,324 | Target Price | 25.65 |
| Oper. Margin | -12.36% | Earnings Date | May 13 | Volume | 283,238 | Change | 0.00% |
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
| Craig-Hallum | Buy | Apr 11, 24 |
| B. Riley Securities | Buy | Mar 22, 24 |
| B. Riley Securities | Buy | Jul 20, 23 |
| Lake Street | Buy | Apr 17, 23 |
| B. Riley Securities | Buy | May 20, 22 |
| Ladenburg Thalmann | Buy | Jul 2, 21 |
| B. Riley Securities | Buy | Apr 7, 20 |
| B. Riley Securities | Buy | Mar 16, 20 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner 10% Owner | Sep 19 | Buy | 14.57 | 20,000 | 291,400 | 3,620,000 | 09/20/23 |
| BAUM MARK L | Chief Executive Offi.. Chief Executive Officer | Aug 14 | Buy | 17.05 | 5,800 | 98,890 | 2,015,461 | 08/15/23 |
| Makary Martin A. | Director Director | Aug 14 | Buy | 16.92 | 20,000 | 338,400 | 45,000 | 08/15/23 |
| BAUM MARK L | Chief Executive Offi.. Chief Executive Officer | Dec 22 | Buy | 13.39 | 25,000 | 334,750 | 1,432,141 | 12/23/22 |
| BOLL ANDREW R. | Chief Financial Offi.. Chief Financial Officer | Dec 22 | Buy | 13.54 | 2,500 | 33,850 | 255,063 | 12/23/22 |
| Makary Martin A. | Director Director | Dec 21 | Buy | 13.37 | 25,000 | 334,250 | 25,000 | 12/23/22 |
| Van Horn R. Lawrence | Director Director | Dec 22 | Buy | 13.42 | 1,860 | 24,961 | 1,860 | 12/23/22 |
| Opaleye Management Inc. | 10% Owner 10% Owner | Sep 28 | Buy | 9.77 | 11,085 | 108,300 | 158,817 | 09/30/22 |
| Opaleye Management Inc. | 10% Owner 10% Owner | Apr 12 | Buy | 6.76 | 41,389 | 279,790 | 157,732 | 04/13/22 |
| BAUM MARK L | Chief Executive Offi.. Chief Executive Officer | Jan 20 | Option | 2.4 | 125,000 | 300,000 | 1,478,547 | 01/21/22 |
| Opaleye Management Inc. | 10% Owner 10% Owner | Aug 19 | Buy | 8.61 | 72,500 | 624,225 | 147,500 | 08/19/21 |